Scarica l'app Stockscreener
2.64
0.38%
-0.010
Dopo l'orario di chiusura:
2.65
0.010
+0.38%
Precedente Chiudi:
$2.65
Aprire:
$2.62
Volume 24 ore:
502.34K
Relative Volume:
0.53
Capitalizzazione di mercato:
$339.61M
Reddito:
$564.17M
Utile/perdita netta:
$37.03M
Rapporto P/E:
24.11
EPS:
0.1095
Flusso di cassa netto:
$-24.46M
1 W Prestazione:
-5.38%
1M Prestazione:
-29.22%
6M Prestazione:
-46.45%
1 anno Prestazione:
-49.71%
Intervallo 1D:
$2.605
$2.71
Intervallo di 1 settimana:
$2.605
$2.815
Portata 52W:
$2.605
$7.0771
Organogenesis Holdings Inc Stock (ORGO) Company Profile
Nome
Organogenesis Holdings Inc
Settore
Telefono
781-575-0775
Indirizzo
85 DAN ROAD, CANTON, MA
Compare ORGO vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ORGO
Organogenesis Holdings Inc
|
2.64 | 339.61M | 564.17M | 37.03M | -24.46M | 0.1095 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.77 | 56.14B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.62 | 48.81B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.03 | 44.67B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.57 | 33.27B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
536.12 | 23.50B | 3.18B | 1.33B | 1.04B | 27.90 |
Organogenesis Holdings Inc Stock (ORGO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-28 | Iniziato | Lake Street | Buy |
| 2024-02-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-06-15 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-05-24 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-11-10 | Downgrade | BTIG Research | Buy → Neutral |
| 2022-08-10 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-01-10 | Iniziato | SVB Leerink | Outperform |
| 2019-08-26 | Ripresa | Credit Suisse | Outperform |
| 2019-05-02 | Iniziato | Credit Suisse | Outperform |
| 2019-04-17 | Iniziato | Oppenheimer | Outperform |
| 2019-04-11 | Iniziato | SunTrust | Buy |
Mostra tutto
Organogenesis Holdings Inc Borsa (ORGO) Ultime notizie
Insider Buying: Organogenesis (NASDAQ:ORGO) Director Buys $13,400.00 in Stock - MarketBeat
Insider Buying: Michael Driscoll Acquires Shares of Organogenesis Holdings Inc (ORGO) - GuruFocus
Organogenesis director Leibowitz buys $13k in ORGO stock - Investing.com
Organogenesis (NASDAQ:ORGO) Director Michael Joseph Driscoll Purchases 10,000 Shares of Stock - MarketBeat
Organogenesis (NASDAQ:ORGO) Upgraded by Wall Street Zen to “Buy” Rating - Defense World
Earnings Beat: Will Organogenesis Holdings Inc. stock gain from lower inflationWeekly Trade Report & Verified Technical Signals - Naître et grandir
Organogenesis (ORGO) VP uses 700 shares to cover tax withholding - Stock Titan
Organogenesis (ORGO) VP amends Form 4 for equity grant and tax withholding - Stock Titan
ORGO (Organogenesis) CEO amends Form 4 for stock grant and tax share disposal - Stock Titan
[Form 4/A] Organogenesis Holdings Inc. Amended Insider Trading Activity - Stock Titan
Organogenesis (ORGO) VP updates Form 4 for award vesting and tax shares - Stock Titan
Organogenesis (NASDAQ: ORGO) officer amends Form 4 for award and tax-withheld shares - Stock Titan
BTIG Research Cuts Organogenesis (NASDAQ:ORGO) Price Target to $8.00 - Defense World
Organogenesis Earnings Call: Record Highs Meet Policy Shock - TipRanks
Organogenesis Holdings Inc. (NASDAQ:ORGO) Q4 2025 Earnings Call Transcript - Insider Monkey
ORGO PE Ratio & Valuation, Is ORGO Overvalued - Intellectia AI
Wall Street Zen Downgrades Organogenesis (NASDAQ:ORGO) to Hold - MarketBeat
Organogenesis Holdings Inc. (ORGO) Stock Analysis: Unveiling a Potential 116% Upside in Healthcare Innovation - DirectorsTalk Interviews
Organogenesis (ORGO) CAO files Form 3 detailing stock and RSUs - Stock Titan
Organogenesis Holdings Reports Q4 2025 Results: Full Earnings Call Transcript - Benzinga
Organogenesis (NASDAQ:ORGO) Price Target Cut to $8.00 by Analysts at BTIG Research - MarketBeat
Organogenesis Holdings (ORGO) Margin-Driven Profitability Shift Tests Revenue Concern Narratives - Sahm
Organogenesis Q4 Earnings Call Highlights - Yahoo Finance
Organogenesis Holdings Inc (ORGO) Q4 2025 Earnings Call Highlights: Record Revenue Growth Amid ... - Investing.com Canada
Earnings call transcript: Organogenesis Q4 2025 beats expectations but faces market challenges - Investing.com Canada
Organogenesis (ORGO) Q4 2025 Earnings Transcript - AOL.com
ORGO: Record Q4 revenue, but 2026 guidance signals a sharp decline before expected recovery - TradingView
Organogenesis: Q4 Earnings Snapshot - Barchart.com
Organogenesis Holdings Inc. (ORGO) Stock Rises on Q4 2025 Earnings - Quiver Quantitative
ORGO: Record 2025 results, but 2026 revenue expected to decline due to CMS changes before recovery - TradingView
Wound-care firm Organogenesis hits record sales, warns 2026 drop up to 38% - Stock Titan
A Preview Of Organogenesis Hldgs's Earnings - Benzinga
Published on: 2026-02-25 08:32:12 - baoquankhu1.vn
Organogenesis Holdings Inc expected to post earnings of 21 cents a shareEarnings Preview - TradingView
Organogenesis Names Patrick McGuire Chief Accounting Officer - The Globe and Mail
Organogenesis (Nasdaq: ORGO) appoints Patrick McGuire as CAO - Stock Titan
Organogenesis Holdings Inc. Announces Executive Changes, Effective February 18, 2026 - marketscreener.com
Organogenesis (NASDAQ: ORGO) legal chief granted options, RSUs and settles taxes - Stock Titan
Executive equity awards at Organogenesis (ORGO) include RSUs, options and tax withholding - Stock Titan
Organogenesis Holdings (NASDAQ: ORGO) COO gets new stock and option awards - Stock Titan
Equity grant gives Organogenesis (ORGO) director 48,828 RSUs vesting 2027 - Stock Titan
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
48,828 RSUs granted to Organogenesis (ORGO) director Arthur Leibowitz - Stock Titan
What’s the fair value of Organogenesis Holdings Inc. stockJuly 2025 Price Swings & Verified Momentum Stock Ideas - mfd.ru
Organogenesis Holdings Inc. (ORGO) Stock Analysis: Exploring a 113% Potential Upside in Healthcare Innovation - DirectorsTalk Interviews
Stem Cell and Regenerative Therapy Markets, 2022-2025 & Forecast to 2030 Featuring Profiles of Leading CompaniesGilead Sciences, Novartis, Bristol-Myers Squibb, Organogenesis, MiMedx Group and More - Yahoo Finance
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026 - The Manila Times
Regenerative medicine firm Organogenesis sets Feb. 26 call on 2025 results - Stock Titan
Organogenesis (NASDAQ: ORGO) CFO uses share dispositions to cover taxes - Stock Titan
Published on: 2026-02-18 01:47:23 - mfd.ru
Organogenesis (NASDAQ: ORGO) holder First Light reports 2.85% stake - Stock Titan
Organogenesis Holdings Inc Azioni (ORGO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.15%
3.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):